High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
暂无分享,去创建一个
J. Gribben | D. Neuberg | J. Aster | J. Ritz | A. Freedman | P. Mauch | R. Soiffer | R. Schlossman | P. Mauch | R. Soiffer | N. Andersen | D. Fisher | L. Nadler | K. Anderson | M. Kroon | David C. Fisher | Neil G. Andersen | Mary Kroon
[1] J. Gribben,et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. , 1996, Blood.
[2] G. Inghirami,et al. Large‐cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome , 1996, British journal of haematology.
[3] E. Noordijk,et al. Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[5] A. Hagenbeek,et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] I. Bernstein,et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.
[7] B. Nathwani,et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.
[8] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[9] J. Gribben,et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow , 1994 .
[10] G. Salles,et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. , 1994, Blood.
[11] F. Berger,et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. , 1994, Blood.
[12] F. Cavalli,et al. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. , 1994, Leukemia & lymphoma.
[13] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[14] M. Williams,et al. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. , 1993, Leukemia.
[15] J. Gribben,et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.
[16] D. Neuberg,et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Pinkus,et al. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Gribben,et al. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. , 1992, Blood.
[19] T. Grogan,et al. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Pileri,et al. Mantle Cell Lymphoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Gribben,et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.
[22] J. Gribben,et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. , 1991, The New England journal of medicine.
[23] D. Weisenburger,et al. Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma , 1990, Cancer.
[24] D. Weisenburger,et al. Mantle zone lymphoma a clinicopathologic study of 22 cases , 1990, Cancer.
[25] E. Jaffe,et al. Lymphocytic lymphoma of intermediate differentiation: morphologic, immunophenotypic, and prognostic factors. , 1990, Journal of the National Cancer Institute.
[26] B. Yeap,et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Lazarus,et al. The Treatment of Progressive Non-Hodgkin's Lymphoma With Intensive Chemoradiotherapy and Autologous Marrow Transplantation , 1990 .
[28] M. Engelhard,et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis , 1989, Hematological oncology.
[29] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[30] S. Horning,et al. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.
[31] T. Lister,et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. , 1983, The American journal of pathology.
[32] D. Weisenburger,et al. Mantle‐zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma , 1982, Cancer.
[33] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[34] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[35] D. Weisenburger,et al. Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. , 1987, Blood.